Aerie Pharmaceuticals (Aerie Pharmaceuticals) EV-to-Revenue : 4.29 (As of Apr. 26, 2024)

Aerie Pharmaceuticals EV-to-Revenue Chart

Aerie Pharmaceuticals Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-Revenue		Get a 7-Day Free Trial					-	59.51	14.60	7.43	2.37

Aerie Pharmaceuticals Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EV-to-Revenue	Get a 7-Day Free Trial															6.00	2.37	2.91	2.50	4.26

Competitive Comparison of Aerie Pharmaceuticals's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Aerie Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aerie Pharmaceuticals's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aerie Pharmaceuticals's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Aerie Pharmaceuticals's EV-to-Revenue falls into.

Aerie Pharmaceuticals EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Aerie Pharmaceuticals's EV-to-Revenue for today is calculated as:

Aerie Pharmaceuticals's current Enterprise Value is $918.1 Mil.
Aerie Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $213.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aerie Pharmaceuticals  (NAS:AERI) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Aerie Pharmaceuticals's PS Ratiofor today is calculated as:

Aerie Pharmaceuticals's share price for today is $15.25.
Aerie Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $4.54.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aerie Pharmaceuticals EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Aerie Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Aerie Pharmaceuticals (Aerie Pharmaceuticals) Business Description